百时美施贵宝：为增长而建——第44届摩根大通医疗健康年会

44thAnnual J.P. MorganHealthcare Conference Christopher Boerner, Ph.D., Board Chair & CEO ForwardLooking Statements This presentation (as well as the oral statements made with respect to the information contained in this presentation) containsstatements about Bristol-Myers SquibbCompany’s (the “Company”) future financial results, plans, business development strategy, anticipated clinical trials, results and regulatory approvals that constituteforward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. All statements that are notstatements of historical facts are, or may be deemed to be, forward-looking statements. Actual results may differ materially from those expressed in, or implied by,these statements as a result of various factors, including, but not limited to: (i) new laws, government actions and regulations, including with respect to pricingcontrols and market access and the imposition of new tariffs, trade restrictions and export regulations, including the potentialfor international reference pricing and Our goal is to build a company that isfinanciallystrongand deliversindustry-leadingsustainable growth into Strong execution supports long-term growth objective Pipeline assets each with multi-billion-dollar potential Significant data expected in 2026…and beyond NME registrational data LCM pivotal data Key next wave early-stage data 2026 2026 2026 •BCMAxGPRC5D dual-targeting CAR TRRMM•Golcadomide1L FL(GOLSEEK-2)•MYK-224HFpEF(AURORA)•PumitamigSolid Tumors2 •AdmilparantIPF(ALOFT-IPF)•Arlo-cel4L+ MM(QUINTESSENTIAL)•IberdomideRRMMPFS (EXCALIBER-RRMM)•MezigdomideRRMM(SUCCESSOR-2)•MilvexianAF(LIBREXIA-AF1)•MilvexianSSP(LIBEXIA-STROKE1) 2027 •AdmilparantPPF(ALOFT-PPF)•CobenfyBipolar-I(BALSAM-1 & 2)•MezigdomideRRMM(SUCCESSOR-1)•Reblozyl1L NTD MDS Associated Anemia(ELEMENT) 2027 •Anti-MTBR-tauAlzheimer’s Disease(TargetTau-1)•FAAH/MAGLAD Agitation(BALANCE-AAD-1)•FAAH/MAGLMS Spasticity(BALANCE-MSS-1) 2027 •AR LDDmCRPC(rechARge) 2028 2028 •Arlo-cel2-4L MM(QUINTESSENTIAL-2)•CobenfyAD Agitation(ADAGIO-2)•CobenfyAD Cognition(MINDSET-1 & 2)•CobenfyAdjunctive Bipolar-1(BALSAM-4)•Golcadomide2L+ FL(GOLSEEK-4)•Iza-brenEGFRm NSCLC(IZABRIGHT-Lung01)•Krazati1L NSCLC PD-L1 ≥50%(KRYSTAL-7) •Atigotatug+ nivolumab1L ES-SCLC(TIGOS)•GolcadomideHigh-Risk 1L LBCL(GOLSEEK-1)•Iza-bren1L TNBC(IZABRIGHT-Breast01)•Pumitamig1L ES-SCLC(ROSETTA-Lung-012)•Zola-celSLE(Breakfree-SLE) Drives wave of 10+ new product launch opportunities by 2030 Multiple paths for capital deployment to create valueenabled by financial strength and discipline Building our long-term growth profile Strategic Priorities Clinical Development Portfolio—Phase I and II Data as of Jan 12th, 2026